AIC
ATRA icon

Ameritas Investment Company’s Atara Biotherapeutics ATRA Stock Holding History

Ameritas Investment Company’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-40
Closed -$35K – 1017
2018
Q4 		$35K Buy
+40
New +$37.1K 0.01% 680

Other funds holding ATRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameritas Investment Company's ATRA Position: Q1 2019 in Review

Ameritas Investment Company sold out of Atara Biotherapeutics (ATRA) in Q1 2019, closing a stake of 40 shares — an estimated $35K sold.

Ameritas Investment Company first reported a position in ATRA in Q4 2018 and held it in 1 quarter. The position peaked at $35K in Q4 2018. 120 funds tracked by Wall St. Rank hold ATRA as of Q1 2019.

  • Ameritas Investment Company reported no remaining Atara Biotherapeutics position as of Q1 2019 after selling out during the quarter.
  • Ameritas Investment Company sold 40 Atara Biotherapeutics shares in Q1 2019, an estimated $35K.
  • Ameritas Investment Company first reported a position in Atara Biotherapeutics in Q4 2018 and held it in 1 quarter.
  • Ameritas Investment Company's Atara Biotherapeutics position peaked at $35K in Q4 2018.
  • 120 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2019.

Based on Ameritas Investment Company's 13F filing for Q1 2019, filed 16 May 2019.